Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2012

View Archived Issues

Phase II safety and immunogenicity data presented for West Nile vaccine

GLYX-13 has antidepressant activity without psychotomimetic effects

Plexxikon presents phase II results for PLX-3397

Enrollment completed in second phase III tedizolid phosphate trial

Inovio Pharmaceuticals reports interim data from its DNA-based flu vaccine study

Portola Pharmaceuticals begins phase II study of PRT-4445

Biotie's phase IIb tozadenant study meets endpoints

Autism Speaks awards grant to Seaside Therapeutics

Administration complete in seasonal flu vaccine phase III trial

Myriad to perform protein biomarker discovery under diabetes collaboration

OncoTherapy Science provides update on COMPETE-PC study

ONO-4059 demonstrates inhibition of arthritis severity and bone damage in vivo

German scientists disclose novel antibodies binding to claudin-6

MilleGen and INSERM prepare new human antibodies for cancer

New agents for obesity presented by Zafgen

New NS5B inhibitors patented by Bristol-Myers Squibb

Teva Pharmaceutical licenses Xenon's pain drug

Merck & Co. divulges new SYK inhibitors

FDA expands indication for Zytiga

BG Medicine obtains CE Mark for CardioSCORE test

Phase III trial of arbaclofen ER tablets for spasticity due to MS begins

Interferon alpha-2b XL shows activity similar to peginterferon alfa-2b

Phase I trial of 4SC's anticancer compound achieves all primary objectives

AstraZeneca and Isis Pharmaceuticals enter strategic alliance for cancer

Oncomatrix and University of Stuttgart form partnership

Mediator of muscle atrophy in critically ill patients identified

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...